<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328740</url>
  </required_header>
  <id_info>
    <org_study_id>TP-1454-101</org_study_id>
    <nct_id>NCT04328740</nct_id>
  </id_info>
  <brief_title>Phase 1 Study of Oral TP-1454</brief_title>
  <official_title>A Phase I, First-in-human, Open-label, Dose Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP 1454 Alone and in Combination With Ipilimumab and Nivolumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sumitomo Dainippon Pharma Oncology, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sumitomo Dainippon Pharma Oncology, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of oral TP-1454 in patients with&#xD;
      advanced metastatic or progressive solid tumors, alone and in combination with Ipilimumab and&#xD;
      Nivolumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
        -  To establish the MTD and/or Recommended Phase 2 Dose (RP2D) of orally administered&#xD;
           TP-1454 monotherapy in patients with advanced metastatic solid tumors&#xD;
&#xD;
        -  To establish the MTD and/or RP2D of orally administered TP-1454 in combination with&#xD;
           ipilimumab and nivolumab in patients with advanced/metastatic solid tumors whom the&#xD;
           investigator deems appropriate for treatment with the defined regimen&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To establish the pharmacokinetic (PK) profile of orally administered TP-1454 alone and&#xD;
           in combination with ipilimumab and nivolumab&#xD;
&#xD;
        -  To observe patients for any evidence of antitumor activity of TP 1454 alone and in&#xD;
           combination with ipilimumab and nivolumab by objective radiographic assessment&#xD;
&#xD;
        -  To study the safety of oral TP-1454 administered as monotherapy and in combination with&#xD;
           ipilimumab and nivolumab in patients with advanced/metastatic solid tumors whom the&#xD;
           investigator deems appropriate for treatment with the defined regimen&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs)</measure>
    <time_frame>28 months</time_frame>
    <description>A DLT is defined as a drug-related toxicity that is observed to occur within the first 21 or 28 days of treatment depending on which arm the patient is enrolled in (monotherapy 28 days; combination 21 days).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine maximum tolerated dose (MTD)</measure>
    <time_frame>28 months</time_frame>
    <description>MTD will be determined based upon toxicity grades which are defined by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 5.0.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Ph 2 dose of TP-1454</measure>
    <time_frame>28 months</time_frame>
    <description>To establish the recommended Ph 2 dose (RP2D) for future studies with TP-1454. MTD, PK and PD data to be reviewed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine antitumor activity of TP-1454.</measure>
    <time_frame>28 months</time_frame>
    <description>Objective radiographic assessment to be performed to determine antitumor activity by Response Evaluation Criteria in Solid Tumors (RECIST criteria v 1.1.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP-1454</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TP-1454, ipilimumab and nivolumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-1454 monotherapy</intervention_name>
    <description>Flat dose once or twice daily, alone</description>
    <arm_group_label>Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TP-1454 combination therapy</intervention_name>
    <description>Flat dose once or twice daily, in combination with ipilimumab and nivolumab</description>
    <arm_group_label>Combination Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Have a histologically confirmed diagnosis of advanced metastatic or progressive solid&#xD;
             tumor,&#xD;
&#xD;
               1. who are refractory to, or intolerant of, established therapy known to provide&#xD;
                  clinical benefit for their condition (Monotherapy Arm)&#xD;
&#xD;
               2. who the investigator deems appropriate for treatment with the defined regimen of&#xD;
                  ipilimumab and nivolumab (Combination Arm).&#xD;
&#xD;
          2. Naïve to prior treatment with any PD1 or CTLA-4 inhibitor (Combination Arm Only)&#xD;
&#xD;
          3. Have measurable as outlined by the Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST) v1.1&#xD;
&#xD;
          4. Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤1&#xD;
&#xD;
          5. Have a life expectancy ≥3 months&#xD;
&#xD;
          6. Be ≥18 years of age&#xD;
&#xD;
          7. Have a negative pregnancy test (if female of childbearing potential)&#xD;
&#xD;
          8. Have acceptable liver function:&#xD;
&#xD;
               1. Bilirubin ≤1.5x upper limit of normal (ULN) (unless associated with Gilbert&#xD;
                  syndrome)&#xD;
&#xD;
               2. Aspartate aminotransferase (AST/SGOT), alanine aminotransferase (ALT/SGPT) and&#xD;
                  alkaline phosphatase ≤2.5x ULN* *If liver metastases are present, then ≤ 3x ULN&#xD;
                  is allowed. ** For patients who will receive ipilimumab and nivolumab in&#xD;
                  combination with TP-1454 then ≤ 3X ULN is allowed&#xD;
&#xD;
          9. Have acceptable renal function: calculated creatinine clearance ≥30 mL/min (using&#xD;
             Cockcroft Gault formula)&#xD;
&#xD;
         10. Have acceptable hematologic status:&#xD;
&#xD;
               1. Granulocyte ≥1500 cells/mm3&#xD;
&#xD;
               2. Platelet count ≥100,000 (plt/mm3)&#xD;
&#xD;
               3. Hemoglobin ≥8 g/dL&#xD;
&#xD;
         11. Have acceptable coagulation status:&#xD;
&#xD;
               1. Prothrombin time (PT) within 1.5x normal limits&#xD;
&#xD;
               2. Activated partial thromboplastin time (aPTT) within 1.5x normal limits&#xD;
&#xD;
         12. Be nonfertile or agree to use an adequate method of contraception. Sexually active&#xD;
             patients and their partners must use an effective method of contraception (hormonal or&#xD;
             barrier method of birth control; or abstinence) prior to study entry and for the&#xD;
             duration of study participation and for at least 3 months (males) and 6 months&#xD;
             (females) after the last study drug dose.&#xD;
&#xD;
             Should a woman become pregnant or suspect she is pregnant while participating in this&#xD;
             study, she should inform her treating physician immediately.&#xD;
&#xD;
         13. Have read and signed the Institutional Review Board (IRB)-approved informed consent&#xD;
             form (ICF) prior to any study-related procedure. (In the event that the patient is&#xD;
             rescreened for study participation or a protocol amendment alters the care of an&#xD;
             ongoing patient, a new ICF must be signed.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. New York Heart Association Class III or IV cardiac disease, or myocardial infarction,&#xD;
             severe unstable angina, coronary/peripheral artery bypass graft, congestive heart&#xD;
             failure within the past 6 months or evidence of ischemia on electrocardiogram (ECG)&#xD;
             within 14 days prior to Cycle 1/Day 1&#xD;
&#xD;
          2. Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of &gt;450&#xD;
             msec in men and &gt;470 msec in women&#xD;
&#xD;
          3. Have a seizure disorder requiring anticonvulsant therapy&#xD;
&#xD;
          4. Have untreated central nervous system (CNS) metastases including carcinomatous&#xD;
             meningitis. Patients with definitively treated (radiotherapy or surgery) CNS&#xD;
             metastases may be eligible if asymptomatic and not receiving corticosteroids in excess&#xD;
             of prednisone 10 mg (or equivalent) per day for ≥2 weeks before first dose of TP-1454&#xD;
&#xD;
          5. Have hypoxemia (defined as resting O2 saturation of ≤90% breathing room air)&#xD;
&#xD;
          6. Have symptomatic interstitial lung disease or radiographic changes in the lungs that&#xD;
             may make detection, diagnosis, or treatment of drug-induced pneumonitis difficult&#xD;
&#xD;
          7. Have undergone major surgery within 2 weeks prior to Cycle 1/Day 1&#xD;
&#xD;
          8. Have active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy&#xD;
&#xD;
          9. Are pregnant or nursing&#xD;
&#xD;
         10. Received treatment with radiation therapy, surgery, chemotherapy, or investigational&#xD;
             therapy within 28 days or 5 half-lives, whichever occurs first, prior to study entry&#xD;
             (6 weeks for nitrosoureas or mitomycin C)&#xD;
&#xD;
         11. Are unwilling or unable to comply with procedures required in this protocol&#xD;
&#xD;
         12. Have known infection with human immunodeficiency virus, hepatitis B, or hepatitis C.&#xD;
             Patients with history of chronic hepatitis that is currently not active are eligible&#xD;
&#xD;
         13. Have a serious nonmalignant disease (eg, hydronephrosis, liver failure, or other&#xD;
             conditions) that could compromise protocol objectives in the opinion of the&#xD;
             Investigator and/or the Sponsor&#xD;
&#xD;
         14. Are currently receiving any other investigational agent&#xD;
&#xD;
         15. Have exhibited allergic reactions to a similar structural compound, biological agent,&#xD;
             or formulation&#xD;
&#xD;
         16. Have malabsorption conditions (eg, Crohn's disease, etc) or have undergone significant&#xD;
             surgery to the gastrointestinal tract that could impair absorption or that could&#xD;
             result in short bowel syndrome with diarrhea due to malabsorption&#xD;
&#xD;
         17. Require systemic corticosteroids greater than the equivalent of 10mg of prednisone or&#xD;
             equivalent alternative steroid (except physiologic dose for adrenal replacement&#xD;
             therapy) or other immunosuppressive agents (e.g., cyclosporine or methotrexate)&#xD;
&#xD;
         18. Have a history of malignancy within the past 24 months except curatively treated in&#xD;
             situ cancers&#xD;
&#xD;
         19. Have active, known, or suspected autoimmune disease with the exception of (combination&#xD;
             arm only):&#xD;
&#xD;
               -  Type I diabetes mellitus&#xD;
&#xD;
               -  Hypothyroidism only requiring hormone replacement&#xD;
&#xD;
               -  Skin disorders not requiring systemic treatment, eg, vitiligo, alopecia, or&#xD;
                  psoriasis&#xD;
&#xD;
         20. Have known EGFR mutations or ALK alterations that are sensitive to targeted therapy in&#xD;
             NSCLC tumor types (combination arm only)&#xD;
&#xD;
         21. Have ≥Grade 2 peripheral neuropathy (combination arm only)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Pennock, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sumitomo Dainippon Pharma Oncology, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holly Beever, RN</last_name>
    <phone>210-365-9014</phone>
    <email>holly.beever@sdponcology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Smith, MSN</last_name>
    <phone>210-414-7702</phone>
    <email>susan.smith@sdponcology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Southern California - Norris Cancer Center and Hoag Memorial Hospital</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033 and 92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony El-Khoueiry, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anthony El-Khoueiry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Vogelzang, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicholas Vogelzang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Garrido-Laguna, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ignacio Garrido-Laguna, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Reilley, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthew Reilley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ariel Nelson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ariel Nelson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 20, 2020</study_first_submitted>
  <study_first_submitted_qc>March 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sumitomo Dainippon Pharma Oncology SDPO</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Advanced Solid Tumors</keyword>
  <keyword>Refractory</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

